Top Markets
#1 Official Trump Official Trump +42.55%
#2 Melania Meme Melania Meme +20.32%
#3 EXOD EXOD +18.93%
#4 Movement Movement +18.82%
#5 Mubarak Mubarak +18.55%
#6 Wrapped POL Wrapped POL +17.43%
#7 POL (ex-MATIC) POL (ex-MATIC) +17.16%
#8 Wrapped STX (Velar) Wrapped STX (Velar) +16.13%
#9 Unit Pump Unit Pump +11.46%
#10 Pump.fun Pump.fun +11.46%
Coin of the day
Official Trump Official Trump
Settings
Language
ENGLISH
Currency
USD
Theme
Tianjin TEDA Biomedical Engineering Company Limited Tianjin TEDA Biomedical Engineering Company Limited

Tianjin TEDA Biomedical Engineering Company Limited

8189
Rank in Stocks #23434
Tianjin TEDA Biomedical Engineering Company Limited, founded in 2000 and based... Tianjin TEDA Biomedical Engineering Company Limited, founded in 2000 and based in Tianjin, People's Republic of China, is a diversified enterprise primarily involved in the research, development, manufacturing, and distribution of biological compound fertilizer products throughout the PRC. Its operations are organized into two main divisions: Biological Compound Fertilizers and Elderly and Health Care Services. The company's agricultural offerings encompass active fertilizers and various tailored blends of nitrogen, phosphorus, and potassium, specifically formulated to promote balanced growth for a range of crops including grains, fruits, and vegetables. Beyond agriculture, Tianjin TEDA Biomedical provides integrated care for the elderly and comprehensive health services. This includes leasing essential equipment for seniors and offering specialized consulting, advisory, and assessment solutions. Furthermore, the company develops and licenses electroencephalography (EEG) diagnosis detection services, utilizing its expertise in EEG technology for diagnostic applications. Its extensive activities also cover the research, development, production, and practical application of biomedical science and technology projects, alongside regional soil resource conditioning and remediation, and the provision of soil environmental quality standards research services.
Share Price
$0.03454008
Last synced: 2026-08-20
Market Cap
$73.71M
Change (1 day)
0.00%
Change (1 year)
-42.57%
Country
CN
Trade Tianjin TEDA Biomedical Engineering Company Limited (8189)

Category

Basic Materials
P/E ratio for Tianjin TEDA Biomedical Engineering Company Limited (8189)
P/E ratio as of 2026 TTM: 0
According to Tianjin TEDA Biomedical Engineering Company Limited latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0. At the end of 2026 the company had a P/E ratio of 0.
P/E ratio history for Tianjin TEDA Biomedical Engineering Company Limited from 2026 to 2026
P/E ratio at the end of each year
Year P/E Ratio Change
Not enough data for the provided dates.
P/E ratio for similar companies or competitors
Company P/E Ratio P/E Ratio Difference Country
Corteva, Inc. Corteva, Inc.
Corteva, Inc.
CTVA.US
 50.78 -
US
Nutrien Ltd. Nutrien Ltd.
Nutrien Ltd.
NTR.TO
 - -
CA
Qinghai Salt Lake Industry Co.,Ltd Qinghai Salt Lake Industry Co.,Ltd
Qinghai Salt Lake Industry Co.,Ltd
000792.SZ
 - -
CN
CF Industries Holdings, Inc. CF Industries Holdings, Inc.
CF Industries Holdings, Inc.
CF.US
 - -
US
Zangge Mining Company Limited Zangge Mining Company Limited
Zangge Mining Company Limited
000408.SZ
 21.39 -
CN
How to read a P/E ratio?

The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share.
A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.

Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.

Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.